Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Travel implications of emerging coronaviruses: SARS and MERS-CoV

Jaffar A. Al-Tawfiq, Alimuddin Zumla, Ziad A. Memish

1. Introduction

The emergence of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) in 2003 in China [1] and of the Middle East Syndrome Coronavirus (MERS-CoV) in the Kingdom of Saudi Arabia (KSA) in 2012 [2] aroused widespread fear and concern for their potential threat to global health security. Several similarities and differences in the epidemiology, clinical features and management of SARS and MERS have been identified [3]. Both SARS-CoV and MERS-CoV viruses are enveloped positive strand RNA beta-coronaviruses. SARS-CoV and MERS-CoV isolated from bats share sequence homology with isolates from humans or civet cat isolates suggest that bats are reservoirs [4-8]. In contrast to MERS-CoV where the Hajj and Umrah (mini-
Hajj) continued to occur without any reported cases, whereas SARS had a significant economical impact. The estimated global economic cost of 100 billion; $US 48 billion in China alone [9,10].

2. SARS and MERS — the initial events

In 27 November 2002, non-official report was issued pointing the presence of an outbreak of respiratory illness in Guangdong Province, China [11]. This was followed in February 2003 by the notification of WHO by the Chinese Ministry of Health of an outbreak of acute respiratory syndrome with 305 cases and 5 deaths [12]. In February—March 2003, there were clusters of atypical pneumonia reported in Vietnam, Hong Kong, Canada, and Singapore [1,13–16]. All these clusters were linked to index patients who stayed on the ninth floor of a hotel in Hong Kong on February 21–22, 2003 [17]. Subsequently, SARS-CoV spread across 30 countries in 6 continents and resulted in a cumulative 8098 cases and 774 deaths (9.5%) [18] with a high rate (21%) of involvement of healthcare workers [19].

With regards to MERS-CoV, the first case of MERS was reported from a patient from Jeddah, Saudi Arabia. The patient had a fulminant disease and he died in September 2012 [2]. Subsequently, MERS-CoV was reported to cause sporadic, intrafamilial or healthcare associated outbreaks infection in Saudi Arabia [20–23], Qatar [24], Jordan [25,26], United Kingdom [27,28], Germany [29], France [30], Tunisia [31], United Arab Emirates [32], and Italy [33]. As of June 26, 2014, there are a total of 707 laboratory-confirmed MERS-CoV infection, including 252 deaths [34].

3. Epidemiology, clinical features and transmission of SARS and MERS

The epidemiology, viral kinetics and transmission patterns of SARS-CoV are well documented [35,36]. SARS-CoV caused higher rates of infections in healthcare settings, and affected healthier and younger persons [37]. The mean age was 56 (range 14–94) compared to 39.9 (range 1–91) years and the male to female ratio was 3:3:1 and 1:1.3; for MERS and SARS respectively [21]. The estimated mean incubation period of SARS was 4.6 days [95% confidence interval (CI) 3.8–5.8 days] [20,38] and the incubation period of MERS was 5.2 days (95% CI 2.2 to 12.4 days) [20].

SARS was found to spread by droplet transmission or direct person-to-person through close contact [36,39–42]. It was estimated that 42% of the early SARS cases in Guangdong where among people involved in animal trade or in food preparation [43]. SARS-CoV antibodies were found in 13% of the animal traders with no diagnosis of SARS compared with 1%–3% of persons in three control groups [44].

The clinical picture of SARS and MERS seems to be similar [3]. In an early comparison between the two diseases, the mortality rate of MERS-CoV was 55% compared to 0–40% for SARS [21], and case-fatality rate for patients with comorbidities of 60% compared to 1–2%, and a mean time from onset to death (days) 16.5 compared to 23.7 for MERS and SARS, respectively [21]. Haemoptysis was more common in MERS (17%) compared to SARS (1%) [21].

Whilst the clinical presentation and transmission characteristics of MERS-CoV infection appear similar to SARS-CoV the geographical distribution indicates that all primary cases of MERS confirmed so far had a link with the Middle East [42] and no global spread outside the Middle East has occurred despite millions of pilgrims who have visited KSA during the past 2 years from 184 countries [43]. This finding indicates that transmission between humans of MERS-CoV is lower than that of SARS-CoV.

4. Animal reservoirs

Both SARS-CoV and MERS-CoV are most likely of zoonotic origin, and the potential animal reservoirs seem to be bats. SARS-CoV-like viruses were isolated from Himalayan palm civets (Paguma larvata) in Guangdong Province, China; from raccoon dogs (Nyctereutes procyonoides); and from a Chinese ferret badger (Meles leucomystax) [45]. Seroprevalence of SARS-CoV antibodies among wild animal trader in Guangdong Province was higher than among workers in other parts of the market or in controls [44,45]. The highest prevalence of antibody (72.7%) was noted among those who traded primarily in palm civets [44].

In vitro studies revealed possible intermediate host for MERS-CoV. Cell lines from goats and camels exhibited efficient replication of the virus [46]. The highest production of virus particles was in goat lung and kidney cells and was comparable to human lung and Vero E6 cells 9 (interferon-deficient primate kidney cells) [46]. MERS-CoV binds to the dipeptidyl peptidase-4 (DPP4s) of camel, goat, cow and sheep [47]. Thus, camels, goats, sheep and cows may be MERS-CV intermediate host reservoir species. In the search of serologic evidence for MERS-CoV infection, neutralising antibodies were not found in sera from goats and cattle [48]. In Saudi Arabia including regions of Riyadh and Al Ahsa, pseudoparticle neutralisation (ppNT) and microneutralisation (MNT) tests detected no antibodies to MERS-CoV in sheep (n = 100), goats (n = 45), cattle (n = 50) and chickens (n = 240) [49].

In a patient with MERS-CoV infection, the patient owned a farm with camels and goats [29]. There were reports of illness affecting the goats and the patient had no direct contact with animals but he ate goat meat and was in contact with an animal caretaker who had respiratory tract disease [29]. One patient had direct contact with a diseased camel shortly before onset of his symptoms [32], and one patient treated a sick camel [50,51]. MERS-CoV from one patient and from the camel were identical [50,51].

Both SARS and MERS caused pulmonary lesions in experimentally challenged cynomolgus macaque monkeys (Macaca fascicularis) [52] and in rhesus macaques, respectively [53]. MERS-CoV has a genetic similarity to bat coronaviruses and thus suggesting an origin in flying mammals [8,54]. In Saudi Arabia, one bat (Taphozous performatus) had a short nucleotide segment identical to the homologous segment of the MERS-CoV virus isolated from an index-case [8]. SARS-related CoVs were identified in Rhinolophus spp. bats in China [55] and Europe [56], and MERS-related CoVs in Pipistrellus bats in Europe [57].

The primary source of MERS-CoV remains unknown but an intermediary animal source other than bats or other animal product is suspected [8,21]. There is increasing evidence of
the presence of MERS antibodies in camels pointing them as possible reservoir or an intermediate host. In an initial study from 50 sera of dromedary camels (Camelus dromedaries) from Oman showed a high-titre of neutralizing antibodies against MERS-CoV [58]. Later on, multiple studies showed positive antibodies in camels from many countries including Spain (Canary Islands), Egypt, Qatar, KSA, UAE, and Jordan [48,50,58–65]. In addition, MERS-CoV was detected by PCR in 2 of 9 (22.2%) camels from the farm of a patient in Jeddah, KSA [50,51], and from 3 of the 14 tested dromedary camels in Qatar [59]. More than one genomic variant was found in dromedary camels which is different from humans where one variant exist and thus the finding suggests interspecies transmission of MERS-CoV of specific genotypes [66]. Currently, the route of animal-to-human transmission is not clearly known [67]. However, MERS-CoV was found in camel milk in 41.7% of 12 tested camel milk [68].

Human to human transmission occurred in the Al-Hasa hospital cluster outbreak [20] via droplet route and possible transmission via contaminated fomites. Whilst initial reports were of hospitalized patients who experienced severe respiratory disease resulting in a high mortality in those with comorbidities [9] subsequent proactive screening of all family and health worker contacts of MERS patients have revealed a spectrum of clinical illness from asymptomatic, mild, moderate to severe disease [44]. MERS had caused higher mortality (60% of patients with coexisting chronic illnesses) than the low mortality of 0–40% for SARS [21].

The concern of in flight transmission of MERS-CoV was evaluated in a mathematical model. The modeling suggests if within-flight transmission of MERS-CoV occurs, one infectious case may result in multiple simultaneous outbreaks in different countries [69]. However, there was no Hajj related MERS-CoV cases [70]. Initial screening for MERS-CoV was positive in a returning woman to Spain but the test was not confirmed [70,71]. A few cases of MERS-CoV related to Umrah were reported.

5. Global concern of MERS-CoV and the impact on the Hajj

The Kingdom of Saudi Arabia had the largest number of reported MERS-CoV patients and the Kingdom hosts one of the largest mass gathering in the world. Thus, the potential for the Hajj to cause a global epidemic was of a great concern. During the Hajj, pilgrims gather in a small area in crowded conditions [72,73]. Annually the Saudi Ministry of Health publishes the Hajj requirement including required vaccines, yellow fever for individuals arriving from countries or areas at risk of yellow fever, poliomyelitis vaccine for travellers arriving from Polio-endemic countries, and Polio-reinfected countries; and quadrivalent (ACYW135) meningococcal vaccine for all visitors arriving for Umra or pilgrimage (Hajj) [74]. In addition, the Saudi Ministry of Health recommends seasonal influenza vaccine for all international pilgrims [74].

The first case of MERS-CoV infection was identified from a patient in Jeddah, Saudi Arabia and the patient died in June 2012 [2,75,76]. Public knowledge of MERS-CoV infection was known only few weeks before the 2012 pilgrimage (Fig. 1) [77]. In 2012 with the emergence of MERS-CoV, the Saudi Ministry of Health, based on available data at that time and in accordance with the WHO advice, did not recommend any travel restrictions [77,78]. The Saudi MoH recommendations also promoted the use of good hand hygiene and cough etiquette [78]. On October 10–31, 2012, the 2012 annual Hajj season was uneventful with no reported MERS-CoV cases among four million pilgrims [79]. Among 300 symptomatic pilgrims with upper respiratory symptoms, none of them tested positive for MERS-CoV [80]. In a cohort of 154 French pilgrims, 83.4% had respiratory symptoms, but none was tested positive for MERS-CoV [81]. A number of sporadic cases and cluster of MERS-CoV occurred in 2012 and 2013 in Saudi Arabia as discussed earlier with clear evidence of human to human transmission among close contacts. As the season for the 2013 Hajj approached, the Saudi MoH further strengthened the recommendations based on the available data. The recommendations stated that people 65 years and older, and those with chronic diseases (such as: heart disease, kidney disease, respiratory disease and diabetes) and pilgrims with immune deficiency (congenital and acquired), malignant and terminal illnesses, pregnant women and children aged under 12 years should postpone the performance of the Hajj and Umrah [74].

An optimistic estimate of MERS-CoV R0 was calculated to be 0.69 compared to the prepandemic R0 for severe acute
respiratory syndrome coronavirus (SARS-CoV) of 0.7—0.80 [82], indicating that MERS-CoV in its current status was unlikely to cause a pandemic [83]. In the event that the next an index patient would infect eight or more individuals then the R0 could be above 1 indicating a pandemic potential [83,84]. The 2012 and 2013 Hajj was completed with no evidence of MERS-CoV[70,85].

6. Advice to travellers to the Middle East

There are no vaccines available which can prevent SARS-CoV or MERS-CoV infection. The UK PHE and the US CDC does not recommend that anyone change their travel plans to the Middle East because of MERS-CoV threat [86]. This CDC travel notice is a Watch (Level 1) which means travellers to the Arabian Peninsula are advised to follow standard precautions, such as hand washing and avoiding contact with people who are ill. It also recommends that all travellers intending to go on the Hajj or Umrah should follow the KSA MoH special recommendations [85]. Because of the risk of MERS, Saudi Arabia recommends that the following groups should postpone their plans for Hajj and Umrah in 2012—2013 and 2013—2014:

- People over 65 years old
- Children under 12 years old
- Pregnant women
- People with chronic diseases (such as heart disease, kidney disease, diabetes, or respiratory disease)
- People with weakened immune systems
- People with cancer or terminal illnesses.
- Travellers are advised to follow routine measures that can help prevent the spread of infections (Table 1).

7. Screening travellers for SARS-CoV or MERS-CoV

Screening travellers for emerging respiratory viruses such as SARS-CoV was recognized as important in 2003 due to its pandemic potential. The basis of such screening to reduce the potential risks of international spread of infectious disease was controversial [87–91]. In an analysis of the effectiveness of non-contact infrared thermometers (NCIT), the calculated positive predictive value (PPV) was 0.9—76.0% and negative predictive value (NPV) was 86.1—99.7% based on fever prevalence of 1.2—16.9% [87]. In a small study of airline travellers, 3 (0.8%) of 359 met the influenza-like illness case definition [89]. Pitman et al. [90] concluded that “entry screening is unlikely to be effective in preventing the importation of either SARS or influenza”. Identifying a maximum of 9% of SARS infected individuals has no significant impact on the course of any subsequent SARS epidemic [90]. In Canada, the use of thermal scanning to detect fever, only 191 (0.025%) of 763,082 screened persons had an initial temperature of >38 °C [91]. The estimated cost of such screening was Can$7.55 million in 4 months [91].

8. Travellers returning from the Middle East

Travellers to the Arabian Peninsula upon return should seek health care if they develop fever, cough or shortness of breath within 14 days of travel. They should volunteer their travel history so it can alert their physician to the possibility of an imported infectious disease. Health care providers should have a high degree of awareness to the possibility of MERS-CoV infection in patients who develop severe acute lower respiratory illness and proactively ask for a history of travel to the Middle East or contact with sick friends or relatives who have been to the Middle East.

9. Conclusion

The origin of SARS-CoV and MERS-CoV is thought to be an animal source with subsequent transmission to humans. The identification of both the intermediate host and the exact route of transmission of MERS-CoV is crucial for the subsequent prevention of the introduction of the virus into the human population. Appropriate initial isolation of MERS-CoV patients would prevent the transmission in the healthcare setting.

Conflict of interest

Authors have no conflict of interest to declare.

Acknowledgements

We acknowledge the support of KSA Ministry of Health. Professor Zumla (A.Z.) acknowledges support from the National Institute of Health Research Biomedical Research Centre, University College London Hospitals, the European and Developing Countries Clinical Trials Partnership and the EC-FW7.

References

[1] Lee N, Hui DS, Wu A, Chan P, Cameron P, Joynt GM, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1986–94.
Zaki AM, van Boeheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814–20.

Hui DS, Memish Z, Zumla A. Severe acute respiratory syndrome vs. the Middle East respiratory syndrome. Curr Opin Pulm Med 2014 May;20(3):233–41.

Lau SK, Woo PC, Li KS, Huang Y, Tsoi HW, Wong BH, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci USA 2005;102:14040–5.

Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 2005;310:676–9.

Shi Z, Hu Z. A review of studies on animal reservoirs of the SARS coronavirus. Virus Res 2008;133:74–87.

Annan A, Baldwin HJ, Corman VM, Klose SM, Owusu M, Nkrumah EE, et al. Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe. Emerg Infect Dis 2013;19:456–9.

Memish ZA, Mishra N, Olival KJ, Fagbo SF, Kapoor V, Epstein JH, et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis 2013;19:1819–23.

Shiu A, Wong Y. Economic impact of SARS: the case of Hong Kong. Asian Econ Pap 2004;3:62–83.

Knobler S, Institute of Medicine (U.S.) Forum on Microbial Threats, Institute of Medicine (U.S.) Board on Global Health. Learning from SARS preparing for the next disease outbreak: workshop summary. Washington DC: National Academies Press; 2004.

Cheng VC, Lau SK, Woo PC, Yuen KY. Review severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev 2007 Oct; 20(4):660–94.

World Health Organization. Weekly epidemiological record. Available at: www.who.int/wer/2013/wer8832.pdf.

Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1997–85.

Poutanen SM, Low DE, Huang Y, Tsoi HW, Wong BH, et al. Identification of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1995–2005.

Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose RB, Dwosh HA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the Greater Toronto area. JAMA 2003;289:2801–9.

Centers for Disease Control and Prevention. Severe acute respiratory syndrome—Singapore, 2003. MMWR 2003;52:405–11.

Parashar UD, Anderson LJ. Severe acute respiratory syndrome: review and lessons of the 2003 outbreak. Int J Epidemiol 2004 Aug;33(4):628–34.

WHO. Summary of probable SARS cases with onset of illness from 1 November to 31 July 2003. Available from: http://www.who.int/csr/sars/country/table2003_09_23/en.

Nuttall I, Dye C. Epidemiology. The SARS wake-up call. Science 2013 Mar 15;339(6125):1287–8.

Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013;369:407–16.

Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013;13:752–61.

Memish ZA, Zumla Al, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM. Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med 2013;368:2487–94.

Al-Ahdal MN, Al-Qahtani AA, Rubino S. Coronavirus respiratory illness in Saudi Arabia. J Infect Dev Ctries 2012;6:94–4.

Centers for Disease Control and Prevention (CDC). Severe respiratory illness associated with a novel coronavirus—Saudi Arabia and Qatar, 2012. MMWR Morb Mortal Wkly Rep 2012;61:820.

Hijawi B, Abdallat M, Sayaydeh A, Alqasrawi S, Haddadin A, Jaourer N, et al. Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation. East Mediterr Health J 2013;19(Suppl. 1):S12–8.

European Centre for Disease Prevention and Control (ECDC). Severe respiratory disease of unknown origin–Jordan-outbreak in ICU. Communicable disease threats report. [Updated 2012 April—May 29; Cited 2013 May 22]. Available from: http://www.ecdc.europa.eu/en/publications/Publications/CDTR201204May2012.pdf.

Health Protection Agency (HPA) UK Novel Coronavirus Investigation Team. Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013. Euro Surveill 2013;18:20427.

Bermingham A, Chand MA, Brown CS, Aarons E, Tong C, Langrish C, et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill 2012;17:20290.

Buchholz U, Mülller MA, Nitsche A, Sanewski A, Wevering J, Bauer-Balci T, et al. Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October–November 2012. Euro Surveill 2013;18:20406.

Mailles A, Blanckaert K, Chaud P, van der Werf S, Lina B, Caro V, et al. First cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013. Euro Surveill 2013;18 pii: 20502.

World Health Organization. Novel coronavirus infection. [Update 2013 Mar 2013 August 5]. Available from: http://www.who.int/csr/don/2013_05_22_ncov/en/.

Drosten C, Seilmaier M, Corman VM, Hartmann W, Scheible G, Sack S, et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis 2013 Sep;13(9):745–51.

ProMed. International Society for infectious diseases. MERS-CoV Eastern Mediterranean (16): Italy Ex Jordan, Contact Cases, WHO. Promed mail. Available from: http://www.promedmail.org/promedprint.php?id=1750425.

WHO. Middle East respiratory syndrome coronavirus (MERS-CoV) – update. Available at: http://www.who.int/csr/don/2014_06_26_mers/en/index.html.

Chu CM, Cheng VC, Hung IF, Chan KS, Tang BS, Tsang TH, et al. Viral load distribution in SARS outbreak. Emerg Infect Dis 2005;11:1882–9.

Yu IT, Wong TW, Chiu YL, Lee N, Li Y. Temporal-spatial analysis of severe acute respiratory syndrome among hospital inpatients. Clin Infect Dis 2005;40:1237–43.

Donnelly CA, Ghani AC, Leung GM, Hedley AJ, Fraser C, Riley S, et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 2003 May 24;361(9371):1761–6.

Leung GM, Hedley AJ, Ho LM, Chau P, Wong IO, Thach TQ, et al. The epidemiology of severe acute respiratory syndrome.
Travel implications of SARS and MERS-CoV

Peiris JS, Yuen KY, Osterhaus AD, Stöhr K. The severe acute respiratory syndrome. N Engl J Med 2003;349:2431–41.

Wong RS, Hui DS. Index patient and SARS outbreak in Hong Kong. Emerg Infect Dis 2004;10:339–41.

Yu IT, Li Y, Wong TW, Chan AT, Lee JH, et al. Evidence of airborne transmission of the severe acute respiratory syndrome virus. N Engl J Med 2004;350:1731–9.

Booth TF, Kournikakis B, Bastian N, Ho J, Kobasa D, Stadnyk L, et al. Detection of airborne severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units. J Infect Dis 2005;191:1472–7.

Breiman RF, Evans MR, Priser W, Maguire J, Schnur A, Li A, et al. Role of China in the quest to define and control severe acute respiratory syndrome. Emerg Infect Dis 2003;9:1037–41.

Centers for Disease Control and Prevention. Prevalence of IgG antibody to SARS-associated coronavirus in animal traders—Guangdong province, China. MMWR 2003;52:966–7.

Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003;302:276–8.

Eckerle I, Corman VM, Müller MA, Lenk M, Ulrich RG, Drosten C. Replicative capacity of MERS coronavirus in livestock cell lines. Emerg Infect Dis 2014 Feb;20(2):276–9.

van Doremalen N, Miazgowicz KL, Milne-Price S, Bushmaker T, Robertson S, Scott D, et al. Host species restriction of middle east respiratory syndrome coronavirus through its receptor dipeptidyl peptidase 4. J Virol 2014 Jun 4. pii: JVI.00676–14. [Epub ahead of print].

Reusken CB, Ababneh M, Raj VS, Meyer B, Eljaraah A, Abuturabush S, et al. Middle East Respiratory Syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. Euro Surveill 2013 Dec;18(50):20662.

Hemida MG, Perera RA, Wang P, Alhammadi MA, Siu LY, Li M, et al. Middle East Respiratory Syndrome (MERS) coronavirus seroprevalence in domestic livestock in Saudi Arabia, 2010 to 2013. Euro Surveill 2013 Dec;18(50):20659.

Memish ZA, Cotten M, Meyer B, Watson SJ, Alsahafi AJ, Al Rabeeah AA, et al. Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013. Emerg Infect Dis 2014 Jun;20(6):1012–5.

Asfar EL, El-Kafrawy SA, Farrra SA, Hassan AM, Al-Saeed MS, Hashem AM, et al. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med 2014 Jun 26;370(26):2499–505.

Fouchier RA, Kuiken T, Schurthen M, van Amerongen G, van Doremalen N, van Doremalen N, et al. Aetiology: Koch’s postulates fulfilled for SARS virus. Nature 2003;423:240.

de Wit E, Rasmussen AL, Falzarno D, Bushmaker T, Feldmann F, Brining DL, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci U S A 2013 Oct 8;110(41):16598–603.

Chastel C. Middle East respiratory syndrome (MERS): bats or dromedary, which of them is responsible? Bull Soc Pathol Exot 2014 May;107(2):69–73.

Yang L, Wu Z, Ren X, Yang F, He G, Zhang J, et al. Novel SARS-like betacoronaviruses in bats, China, 2011. Emerg Infect Dis 2013 Jun;19(6):989–91.

Drexler JF, Gloza-Rausch F, Glende J, Corman VM, Muth D, Goetsche M, et al. Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequences. J Virol 2010 Nov;84(11):11336–49.

Lelli D, Papetti A, Sabelci C, Rosti E, Moreno A, Boniotti MB. Detection of coronaviruses in bats of various species in Italy. Viruses 2013 Oct 31;5(11):2679–89. http://dx.doi.org/10.3390/v5112679.

Reusken CB, Haagmans BL, Müller MA, Gutierrez C, Godeke GJ, Meyer B, et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis 2013;13(10):859–66.

Haagmans BL, Al Dhahiry SH, Reusken CB, Raj VS, Galiano M, Myers R, et al. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect Dis 2014;14(2):140–5.

Perera RA, Wang P, Gomaa MR, El-Shenemy R, Kandell A, Bagato O, et al. Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. Euro Surveill 2013;18(36):ii.

Meyer B, Müller MA, Corman VM, Reusken CB, Ritz D, Godeke GJ, et al. Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013. Emerg Infect Dis 2014;20(4):552–9.

Chu DK, Poon LL, Gomaa MM, Shehata MM, Perera RA, Abu Zeid D, et al. MERS coronaviruses in dromedary camels, Egypt. Emerg Infect Dis 2014;20(6):1049–53.

Nowotny N, Kolodziejek J. Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels, Oman, 2013. Euro Surveill 2014;19(16). pii: 20781.

Alexandersen S, Kobinger GP, Soule G, Wernery U. Middle East respiratory syndrome coronavirus antibody reactors among camels in Dubai, United Arab Emirates, in 2005. Transbound Emerg Dis;61(2):105–108.

Reusken CBEM, Messadi L, Feyisa A, Uaramu H, Godeke G-J, Danmarwa A, et al. Geographic distribution of MERS coronavirus among dromedary camels, Africa. Emerg Infect Dis 2014 Jul. http://dx.doi.org/10.3201/eid2007.140590 [date cited].

Briese T, Mishra N, Jain K, Zalmout IS, Jabado OJ, Karesh WB, et al. Middle East respiratory syndrome coronavirus quasispecies that include homologues of human isolates revealed through whole-genome analysis and virus cultured from dromedary camels in Saudi Arabia. MBio 2014; m5(3). pii: e01146–14.

Nishiura H, Ejima K, Mizumoto K. Missing information in animal surveillance of MERS-CoV. Lancet Infect Dis 2014;14(2):100.

Reusken CB, Farag E, Jones G, Godeke G, El-Sayed A, Pas S, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) RNA and neutralizing antibodies in milk collected according to local customs from dromedary camels, Qatar, April 2014. Euro Surveill 2014;19(23). pii: 20829.

Coburn BJ, Blower S. Predicting the potential for within-flight transmission and global dissemination of MERS. Lancet Infect Dis 2014 Feb;14(2):99.

Rashid H, Azeem MI, Heron L, Haworth E, Booy R, Memish ZA. Has Hajj-associated MERS-CoV transmission occurred? The case for effective post-Hajj surveillance for infection. Clin Microbiol Infect 2013 Dec 7. http://dx.doi.org/10.1111/1469-0691.12492 [Epub ahead of print].

European Centre for Disease Prevention and Control. Rapid risk Assessment: severe respiratory disease associated with Middle East respiratory syndrome coronavirus (MERS-CoV), Available at: http://ecdc.europa.eu/en/publications/
Ahmed QA, Arabi YM, Memish ZA. Health risks at the Hajj. Lancet 2006;367:1008–15.

Al-Tawfiq JA, Memish ZA. Mass gatherings and infectious diseases: prevention, detection, and control. Infect Dis Clin North Am 2012;26:725–37.

Memish ZA, Al Rabeeah AA. Health conditions for travellers to Saudi Arabia for the Umra and pilgrimage to Mecca (Hajj) — 2014. J Epidemiol Glob Health 2014 Jun;4(2):73–5.

Al-Tawfiq JA, Smallwood CA, Arbuthnott KG, Malik MS, Barbeschi M, Memish ZA. Emerging respiratory and novel coronavirus 2012 infections and mass gatherings. East Mediterr Health J 2013;19(Suppl. 1):548–54.

Memish ZA, Zumla A, Al-Tawfiq JA. How great is the risk of Middle East respiratory syndrome coronavirus to the global population? Expert Rev Anti Infect Ther 2013 Oct;11(10):979–81.

Novel coronavirus — Eastern Mediterranean (03): Saudi comment, 12 February 2013. ProMed; 2013. archive number 20130212.1540011.

Gautret P, Charrel R, Belhouchat K, Drali T, Benkouiten S, Nougarede A, et al. Lack of nasal carriage of novel coronavirus (HCoVEMC) in French Hajj pilgrims returning from the Hajj 2012, despite a high rate of respiratory symptoms. Clin Microbiol Infect 2013;19:e315–7.

Wallinga J, Teunis P. Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures. Am J Epidemiol 2004 Sep 15;160(6):509–16.

Breban R, Riou J, Fontanet A. Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk. Lancet 2013;382(9893):694–9.

Bauch CT, Oraby T. Assessing the pandemic potential of MERS-CoV. Lancet 2013 Aug 24;382(9893):662–4.

Memish ZA, Al-Rabeeah AA. Public health management of mass gatherings: the Saudi Arabian experience with MERS-CoV. Bull World Health Organ 2013 Dec 1;91(12):899–899A.

CDC. A Novel Coronavirus Called "MERS-CoV" in the Arabian Peninsula. Available at: http://wwwnc.cdc.gov/travel/notices/watch/coronavirus-arabian-peninsula-uk.

Bitar D, Goubar A, Desenclos JC. International travels and fever screening during epidemics: a literature review on the effectiveness and potential use of non-contact infrared thermometers. Euro Surveill 2009 Feb 12;14(6).

Pitman RJ, Cooper BS, Trotter CL, Gay NJ, Edmunds WJ. Entry screening for severe acute respiratory syndrome (SARS) or influenza: policy evaluation. BMJ 2005 Nov 26;331(7527):1242–3.

St John RK, King A, de Jong D, Bodie-Collins M, Squires SG, Tam TW. Border screening for SARS. Emerg Infect Dis 2005 Jan;11(1):6–10.